Coherus Biosciences Inc’s recent filing unveils that its President & CEO Lanfear Dennis M unloaded Company’s shares for reported $0.45 million on Nov 22 ’23. In the deal valued at $2.02 per share,223,100 shares were sold. As a result of this transaction, Lanfear Dennis M now holds 731,693 shares worth roughly $1.6 million.
Robert W. Baird initiated its Coherus Biosciences Inc [CHRS] rating to an Outperform in a research note published on November 17, 2023; the price target was $11. A number of analysts have revised their coverage, including Maxim Group’s analysts, who decreased its forecast for the stock in early November from “a Buy” to “a Hold”. Citigroup began covering CHRS with “Buy” recommendation on July 24, 2023. Truist started covering the stock on May 01, 2023. It rated CHRS as “a Buy”.
Price Performance Review of CHRS
On Monday, Coherus Biosciences Inc [NASDAQ:CHRS] saw its stock jump 5.31% to $2.18. Over the last five days, the stock has lost -0.91%. Coherus Biosciences Inc shares have fallen nearly -34.53% since the year began. Nevertheless, the stocks have fallen -72.65% over the past one year. While a 52-week high of $8.33 was reached on 01/02/24, a 52-week low of $1.43 was recorded on 02/05/24. SMA at 50 days reached $2.38, while 200 days put it at $3.16. A total of 1.5 million shares were traded, compared to the trading of 2.88 million shares in the previous session.
Levels Of Support And Resistance For CHRS Stock
The 24-hour chart illustrates a support level at 2.08, which if violated will result in even more drops to 1.99. On the upside, there is a resistance level at 2.23. A further resistance level may holdings at 2.29. The Relative Strength Index (RSI) on the 14-day chart is 44.40, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.20, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 65.15%. Stochastics %K at 18.21% indicates the stock is a buying.
